Skip to content
buyWeak

Suvretta Capital Management, LLC bought $403k of BNTC

director, owner at Benitec Biopharma Inc.. 42,000 shares at an average of $9.60, traded Dec 3, 2024, filed Dec 5, 2024.

Conviction score
31
Value
$403k
42,000 shares
Holdings after
955,124
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $403k at market
    +16
  • Relative to holdings
    Under 1% of holdings (0.5%)
    -5
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    2 buys in 90 days
    +5
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +23.7%, 3m +32.8%, 6m +55.1%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BNTCOct 9, 2026 · close 8.87
Since filing Dec 5, 2024: -9.3%SPY +31.3% · excess -40.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000899140-24-001318, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 3, 2024POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+37,190$9.60$357k7,957,365Dec 5, 2024
Dec 3, 2024POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+4,810$9.60$46k955,124Dec 5, 2024

Related signals

Other insiders at Benitec Biopharma Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
49Moderate
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$1.9M
144,223 shares
+2%
42Moderate
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$539k
46,141 shares
+0%
47Moderate
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$20M
1,481,481 shares
+17%
31Weak
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$212k
16,497 shares
+0%
47Moderate
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$12M
900,000 shares
+11%
33Weak
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$527k
47,520 shares
+1%
26Weak
BNTCbuy
Benitec Biopharma Inc.
Suvretta Capital Management, LLC
director, owner
$417k
41,436 shares
+1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Suvretta Capital Management, LLC bought $403k of BNTC | InsiderTell